Hepatitis A vaccine liposomal - Crucell

Drug Profile

Hepatitis A vaccine liposomal - Crucell

Alternative Names: Epaxal; Epaxal Junior; HAVpur; HAVpur Junior; IRIV-hepatitis A vaccine; Virohep-A; Virohep-A Junior

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Berna Biotech
  • Developer Crucell; GlaxoSmithKline
  • Class Hepatitis A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis A

Most Recent Events

  • 28 Feb 2011 Crucell completed enrolment in a phase III, long-term follow-up trial for Hepatitis A (Prevention, In infants) in Israel (NCT01307436)
  • 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
  • 01 Jan 2010 Registered for Hepatitis A in Israel (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top